Statistically significant lower risk is seen for progression, cases, and viral clearance. 3 studies from 3 independent teams in 3 countries show significant improvements.
Meta analysis using the most serious outcome reported shows 79% [66‑87%] lower risk. Currently all studies are RCTs.
Currently there is limited data, with only 509 patients in trials to date. Studies to date are from only 3 different groups.
4 RCTs with 512 patients have not reported results (up to 2 years late).
No treatment or intervention is 100% effective. All practical, effective, and safe means should be used based on risk/benefit analysis. Multiple treatments are typically used in combination, and other treatments may be more effective. Chlorhexidine may be detrimental to the natural microbiome, raising concern for side effects, especially with prolonged or excessive use.
All data to reproduce this paper and sources are in the appendix.
Covid Analysis et al., May 2024, preprint, 1 author.